Look for this conference — in a very understated way — to make clear that additional R&D headcount reductions are underway across most of Merck’s business lines. I predict Merck execs will do so, while highlighting the “new” areas of emphasis for its streamlined research and development operations. At the end of the day, my guess is that probably another 10 percent of R&D headcount is going away. Unfortunate.
Per an overnight presser from Whitehouse Station — and as promised on the Q3 2011 earnings webcast:
. . . .Merck will hold its R&D and Business Briefing at 8:30 a.m. EST on Thursday, Nov. 10 at its corporate headquarters in Whitehouse Station, NJ. During the event, members of Merck’s senior management will detail the company’s research strategy, showcase candidates from the R&D pipeline and provide an update of business progress. There will be a live audio webcast of the event on Merck’s website. . . .
We will post highlights, and editorial analysis here. Do stop back on the morning of the 10th, then. . . .